Directorate Change

Physiomics announces appointment of David Evans as Chairman          

Oxford, UK, 26 August 2005 The Board of Physiomics plc (AIM:PYC), a European
systems biology simulation company, today announces the immediate appointment
of Mr David Evans as Non-Executive Chairman. He succeeds Dr Stephen Parker who
leaves the board to pursue other opportunities.

David Evans MBA has extensive small company experience particularly in the life
sciences sector. Mr Evans became Managing Director of Shield Diagnostics in
1997, having previously been Finance Director. As Managing Director, he led the
merger with Axis to form Axis-Shield in 1999. He was deputy managing director
of the merged company until 2000.

Since then, Mr Evans has held a number of non-executive directorships in
several quoted and unquoted companies.

Mr Evans is, or has been, a director of the following companies in the previous
five years:

Present directorships                   Past directorships                     
                                                                               
BBI Holdings plc                        Acolyte Biomedica Limited              
                                                                               
Chromogenex plc                         Axis-Shield plc                        
                                                                               
Eurodiagnostica BV                      Axis-Shield Diagnostics Limited        
                                                                               
Immunodiagnostic Systems Holdings plc   British Biocell International Limited  
                                                                               
Microtest Matrices Limited              CY Realisations Limited                
                                                                               
Omega Diagnostics Limited               Guardian Laboratories Limited          
                                                                               
Platform Diagnostics Limited            Haptogen Limited                       
                                                                               
Storyland Limited                       Immunodiagnostic Systems Limited       
                                                                               
                                        Nestech Limited                        
                                                                               
                                        Plasmatec Laboratory Products Limited  
                                                                               
                                        Porton Cambridge Limited               
                                                                               
                                        Scottish Enterprise Tayside            
                                                                               
                                        Shield Immunologicals Limited          

David Evans was a director of CY Realisations Limited (previously Cytocell
Limited) that was placed into creditors voluntary liquidation in April 2003,
and a director of Lineplan Limited that was placed into creditors voluntary
liquidation in May 2000 with a deficit to creditors of £30,582. There is no
other information that is required to be disclosed pursuant to Schedule 2
paragraph (g) of the AIM Rules.

Stephen Parker joined Physiomics in March 2004 as Chairman and successfully
steered the business through its initial public offering at the end of 2004. Dr
Parker has recently become a Partner of Celtic Pharma Management LP, a new
private equity fund specialising in late stage pharmaceutical projects. Celtic
recently announced the acquisition of Xenova Group plc, its first major
investment.

Dr Stephen Parker commented 'The progress of the Company since March 2004 has
been substantial and this is an exciting period of development for Physiomics.
I regret that my commitments with Celtic Pharma have required me to step down,
but have every confidence that the business will to continue to grow
successfully under the leadership of David Evans and John Savin.'

Dr John Savin, CEO of Physiomics, commented 'The Board wishes to express its
thanks to Stephen Parker for his major contribution over a period of profound
change for the Company. On behalf of the Board I wish him every success in his
new role.'

Mr David Evans commented 'I am delighted to be joining Physiomics at this
exciting stage in its development. The company has a unique offering in
applying systems biology to the drug development process and I look forward to
working with the Physiomics team to maximise this potential.'

                                    --ENDS-                                    

For further information please contact:

 

Physiomics plc

Mr David Evans (Chairman) Tel: [phone]

Dr John Savin (CEO) Tel: [phone]

 

Northbank Communications Tel: [phone]

Emma Palmer (financial enquiries)

Fiona Brown/Rowan Minnion (media enquiries)

Notes to Editors

Physiomics plc

Physiomics plc (AIM:PYC) is a systems biology company applying computer-based
simulations of cell behaviour in drug development, aimed at reducing the high
cost and attrition rates of clinical trials. As 80-90 per cent of all clinical
drug candidates fail to reach the market, estimates show even a ten per cent.
overall improvement in success rates could reduce the cost of one drug's
development by up to $242 million, from the current estimate of around $800
million.

Physiomics is currently focused on optimising the design of cancer clinical
trials as a service to major pharmaceutical companies. In addition, it has
secured an option to in-license two innovative molecules in the cancer area
from Cronos Therapeutics. Physiomics has a major collaboration with Bayer
Technology Services GmbH to develop globally clinical response prediction
services using both companies' proprietary technologies and mathematical cell
models, including the SystemCell® technology developed by Physiomics. In June
2005, Physiomics became is a distributor of Bayer's PK-Sim® product for
understanding the way pharmaceuticals are distributed round the body.
Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in
2004.

For further information, please visit www.physiomics-plc.com

SystemCell is a registered trademark of Physiomics plc



                                Physiomics plc                                 

                Registered in England and Wales Number 4225086                 

Registered Office: The Magdalen Centre, Oxford Science Park, Oxford OX4 4GA, UK